Bio-Techne Reports Mixed Q3 2026: Revenue Declines Amid Segment Shifts
Event summary
- Bio-Techne's Q3 2026 revenue declined 2% YoY to $311.4M, impacted by prior-year GMP fast-track orders and timing of large Commercial Supply shipments.
- GAAP EPS increased to $0.32 from $0.14, while adjusted EPS decreased to $0.53 from $0.56.
- Large pharma delivered six consecutive quarters of double-digit growth, offset by lagging spending from emerging biotech.
- Spatial Biology segment grew mid-teens, while GMP proteins (excluding fast-track customers) surged nearly 50%.
- Protein Sciences segment revenue decreased 1%, while Diagnostics and Spatial Biology segment revenue fell 4%.
The big picture
Bio-Techne's mixed Q3 results reflect broader industry trends of uneven demand across biotech and pharma sectors. The company's strategic focus on high-value applications from discovery to diagnostics positions it to navigate market volatility, but execution will depend on sustaining momentum in large pharma while addressing softness in emerging biotech. The divestiture of Exosome Diagnostics and profitability initiatives signal a shift toward operational discipline amid shifting end-market dynamics.
What we're watching
- Market Segmentation
- How Bio-Techne will balance growth in large pharma against lagging demand from emerging biotech and academic markets.
- Profitability Initiatives
- Whether ongoing cost-cutting measures can offset volume and product mix pressures in key segments.
- Strategic Realignment
- The pace at which Bio-Techne can realign its portfolio to capitalize on high-growth areas like Spatial Biology and GMP proteins.
Related topics